Flomics will validate its cf-RNA liquid biopsy for 7 cancer types, adding liver and hematological tumors to its early detection pipeline.
Flomics announces the launch of BIOTEM (“Biomarkers for Early Multicancer Detection”), a project to validate our proprietary liquid biopsy platform. Building on our recent advances that achieved 80% sensitivity for Stage I cancers, BIOTEM aims to refine our cell-free RNA (cf-RNA) technology for the five cancers already in our pipeline — breast, colorectal, lung, pancreas, and prostate — while expanding its detection capabilities to liver cancer and hematological tumors.
To achieve this goal, we will collaborate with a network of national and international biobanks and hospitals to analyze a cohort of 1,500 retrospective and prospective samples. This data will be used to train our classification algorithms, with the objective of increasing sensitivity to over 95% in early disease stages. This is a crucial step towards clinical validation and regulatory certification (IVDR).
Funding Acknowledgment. This project has been funded by the Centre for the Development of Technology and Innovation (CDTI) with funds from the European Union through NextGenerationEU funds,European Union’s, within the framework of the Recovery, Transformation and Resilience Plan (PERTE for Vanguard Health).
This funding is key to accelerating Flomics’ roadmap toward market access and reinforces our commitment to revolutionizing early cancer diagnosis through precision medicine.
